Sign in Sign up for free

Last updated: 26 July 2024 at 6:57pm EST

Leslie Williams Net Worth




The estimated Net Worth of Leslie J. Williams is at least $182 Thousand dollars as of 14 June 2019. Ms. Williams owns over 4,500 units of Ocular Therapeutix Inc stock worth over $37,980 and over the last 6 years she sold OCUL stock worth over $0. In addition, she makes $144,470 as Independent Director at Ocular Therapeutix Inc.

Ms. Williams OCUL stock SEC Form 4 insiders trading

Leslie has made over 1 trades of the Ocular Therapeutix Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 4,500 units of OCUL stock worth $19,800 on 14 June 2019.

The largest trade she's ever made was buying 4,500 units of Ocular Therapeutix Inc stock on 14 June 2019 worth over $19,800. On average, Leslie trades about 450 units every 0 days since 2019. As of 14 June 2019 she still owns at least 4,500 units of Ocular Therapeutix Inc stock.

You can see the complete history of Ms. Williams stock trades at the bottom of the page.





Leslie Williams biography

Leslie J. Williams serves as Independent Director of the Company. Ms. Williams was the founder of ImmusanT, Inc., a biotechnology company, and served as a member of its board of directors and as its President and Chief Executive Officer since its inception in December 2010 until the completion of its reverse merger in December 2019. She served as the President and Chief Executive Officer and as a member of the board of directors of Ventaira Pharmaceuticals, Inc., a specialty pharmaceutical company, from 2004 until 2008. Previously, Ms. Williams also was a venture partner at Battelle Ventures, an early stage venture capital fund, and served on the boards of directors of Hepregen Inc., a company engaged in the development and marketing of proprietary drug screening products, and of CDI Bioscience, Inc., a cell line engineering and contract manufacturing company, and of The Capital Network, a non-profit organization providing entrepreneurial education opportunities. Ms. Williams is a member of the board of advisors of Life Science Cares, the executive board of the University of Iowa College of Pharmacy, founding member of Mass VX advisory committee and of the editorial advisory boards of the Life Science Leader and the Journal of Advanced Therapies and Medical Innovation Sciences. Ms. Williams received a B.S. in Nursing from the University of Iowa and a M.B.A. from the Washington University John Olin School of Business.

What is the salary of Leslie Williams?

As the Independent Director of Ocular Therapeutix Inc, the total compensation of Leslie Williams at Ocular Therapeutix Inc is $144,470. There are 8 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.



How old is Leslie Williams?

Leslie Williams is 60, she's been the Independent Director of Ocular Therapeutix Inc since 2019. There are 5 older and 10 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.

What's Leslie Williams's mailing address?

Leslie's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.

Insiders trading at Ocular Therapeutix Inc

Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer, and Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.



What does Ocular Therapeutix Inc do?

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib



What does Ocular Therapeutix Inc's logo look like?

Ocular Therapeutix Inc logo

Complete history of Ms. Williams stock trades at Ocular Therapeutix Inc and Windtree Therapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
14 Jun 2019 OCUL Ocular Therapeutix Inc Leslie J. Williams
Director
 Buy 4,500 $4.40 $19,800
14 Jun 2019
4,500 ↗


Ocular Therapeutix Inc executives and stock owners

Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: